<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03313544</url>
  </required_header>
  <id_info>
    <org_study_id>2017-01</org_study_id>
    <secondary_id>2017-001197-42</secondary_id>
    <nct_id>NCT03313544</nct_id>
  </id_info>
  <brief_title>Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting PD-1</brief_title>
  <official_title>Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting Programmed Cell Death 1 (PD-1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, monocentric clinical study. Patients selected for nivolumab therapy in AP-HM for&#xD;
      melanoma and non-small cell lung cancer will be eligible. Do not include patients with&#xD;
      conditions that do not allow MRI, prior cardiovascular disease with LVEF&lt;50%, cardiomyopathy,&#xD;
      history of cardiac arrhythmia, history of cardiovascular toxicity under anticancer therapy,&#xD;
      coronary artery disease or stroke less than 3 months Therapeutic management will not be&#xD;
      modified and treatment will be administrated as usual.&#xD;
&#xD;
      Cardiovascular follow up will be identical to that recommended and realized in current care&#xD;
      in the Cardio-Oncology unit of AP-HM. It will include clinical, biological (BNP and troponin)&#xD;
      and trans-thoracic echocardiography (TTE) at baseline and then at 1, 3 and 6 months.&#xD;
      Auto-antibodies against troponin I assay will be performed to avoid false negatives of normal&#xD;
      blood level of troponin I at baseline and then at 6 months. Cardiac MRI will be performed as&#xD;
      well at baseline and at the end of the study (6 months). MRI is the gold standard for&#xD;
      ventricular function evaluation.&#xD;
&#xD;
      Primary endpoint will be left ventricular function evolution evaluated by global longitudinal&#xD;
      strain (GLS, 2D speckles tracking) in TTE. Secondary endpoints will be left and right&#xD;
      ventricular function parameters: LEVF by TTE and MRI, left ventricular indexed volumes by TTE&#xD;
      and MRI, right ejection ventricular function and indexed volumes by TTE and MRI, systolic&#xD;
      pulmonary arterial pressure by TTE, serum troponin I and BNP, arrhythmias and conduction&#xD;
      disorders on the electrocardiogram (ECG).&#xD;
&#xD;
      Number of required subjects: GLS is recommended for following up left ventricular function&#xD;
      under anticancer treatments. Based on the hypothesis of a significant GLS decrease (15%) in&#xD;
      20% of cases with alpha risk of 0.05 and accuracy of 0.12 which means expected confidence&#xD;
      interval of 0.08-0.32, then the number of required subjects is 50 patients.&#xD;
&#xD;
      The inclusion period will be 18 months with a follow up if 6 months, ie a total duration of&#xD;
      the study of 24 months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">October 2017</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>systolic pulmonary arterial pressure</measure>
    <time_frame>6 months</time_frame>
    <description>trans-thoracic echocardiography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ventricular function evaluation.</measure>
    <time_frame>6 MONTHS</time_frame>
    <description>MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum troponin I</measure>
    <time_frame>1,3, 6 months</time_frame>
    <description>BLOOD SAMPLES</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain natriuretic peptide (BNP)</measure>
    <time_frame>1,3, 6 months</time_frame>
    <description>BLOOD SAMPLES</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Melanoma</condition>
  <condition>Non-small Cell</condition>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>NIVOLUMAB PATIENTS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>NIVOLUMAB</description>
    <arm_group_label>NIVOLUMAB PATIENTS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>Cardiac MRI 6 MONTHS</description>
    <arm_group_label>NIVOLUMAB PATIENTS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BLOOD SAMPLES</intervention_name>
    <description>biological (BNP and troponin)</description>
    <arm_group_label>NIVOLUMAB PATIENTS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>trans-thoracic echocardiography</intervention_name>
    <description>1, 3 and 6 months</description>
    <arm_group_label>NIVOLUMAB PATIENTS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        patients treated with nivolumab&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;18 years&#xD;
&#xD;
          -  Preliminary cardiac disease with FeVG &lt;50%&#xD;
&#xD;
          -  Cardiomyopathy dilated, hypertrophic or restrictive&#xD;
&#xD;
          -  History of cardiac arrhythmia&#xD;
&#xD;
          -  History of cardiac toxicity under another anti-cancer treatment&#xD;
&#xD;
          -  Known coronary disease&#xD;
&#xD;
          -  History of stroke less than 3 months old&#xD;
&#xD;
          -  Patient not wishing to participate in the study&#xD;
&#xD;
          -  Vulnerable persons (pregnant women, adults under guardianship or guardianship, persons&#xD;
             deprived of their liberty)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Olivier ARNAUD</last_name>
    <role>Study Director</role>
    <affiliation>assistance publique h√¥pitaux de marseille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>jennifer CAUTELA</last_name>
    <phone>0491968289</phone>
    <email>jennifer.cautela@ap-hm.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>ALEXANDRA GIULIANI</last_name>
    <phone>0491382747</phone>
    <email>drci@ap-hm.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Assistance Publique Hopitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13354</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>JENNIFER CAUTELA</last_name>
      <email>jennifer.cautela@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>jennifer CAUTELA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>October 10, 2017</study_first_submitted>
  <study_first_submitted_qc>October 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2017</study_first_posted>
  <last_update_submitted>October 13, 2017</last_update_submitted>
  <last_update_submitted_qc>October 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

